PMID- 16965686
OWN - NLM
STAT- MEDLINE
DCOM- 20090528
LR  - 20181201
VI  - 25
IP  - 8
DP  - 2006 Aug
TI  - [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation 
      for treatment of malignant hematological disease].
PG  - 1019-22
AB  - BACKGROUND & OBJECTIVE: Allogeneic hematopoietic stem cell transplantation 
      (allo-HSCT) is the most effective method to treat malignant hematological 
      disease. However the human leukocyte antigen (HLA)-matched sibling donors can be 
      found for only 25%-30% patients. The probability of finding an unrelated matched 
      donor is 1/50000-1/100000, or even lower. If we choose haploid HLA-matched 
      hematopoietic stem cell transplantation instead, we may be able to find donors 
      for 90% patients. Our present study was to explore the feasibility of allo-HSCT 
      by using haploid HLA-matched donor in treatment for malignant hematological 
      disease. METHODS: Twenty-five patients with malignant hematological disease 
      received allo-HSCT with HLA 2 or 3 antigen mismatched related donors. All 
      patients were treated with intensive immunosuppression, granulocyte colony 
      stimulating factor (G-CSF) mobilization, antithymocyte globulin (ATG) and 
      combination of bone marrow and peripheral blood stem cell transplantation. The 
      conditioning regimen was intensified and prolonged by using the combination of 
      cyclosporine (Cs) A, MMF, ATG and anti-CD25 antibody for graft-versus-host 
      disease (GVHD) prophylaxis. RESULTS: All patients achieved sustained, full 
      donortype engraftment. Acute GVHD occurred in 21 of 25 patients. Eight of them 
      were grade I aGVHD, six grade II aGVHD, two grade III aGVHD and five grade IV 
      aGVHD. The cumulative incidence of grade II-IV aGVHD was 48%,and grade III-IV 
      aGVHD was 28.57%. Chronic GVHD was observed in 12 of 25 patients and none of them 
      developed extensive cGVHD. Sixteen patients were alive and disease free, with 
      64.0+/- 2.98% 1 year disease-free survival rate. One year overall survival rate 
      was 64.0+/-3.08%. Nine patients died, 1 from relapse and 8 from transplantation 
      related mortality. CONCLUSIONS: Haploid HLA-matched allo-HSCT is a relatively 
      efficient method for the treatment of patients with malignant hematological 
      disease, who have no related matched donors. Nevertheless, strict administration 
      should be carried out since it's a high risk approach.
FAU - Sun, Ai-Ning
AU  - Sun AN
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Jiangsu, Suzhou 215006, P. R. China.
FAU - Wu, De-Pei
AU  - Wu DP
FAU - Wang, Ying
AU  - Wang Y
FAU - Qiu, Hui-Ying
AU  - Qiu HY
FAU - Jin, Zheng-Ming
AU  - Jin ZM
FAU - Miao, Miao
AU  - Miao M
FAU - Tang, Xiao-Wen
AU  - Tang XW
FAU - Fu, Zheng-Zheng
AU  - Fu ZZ
FAU - Ma, Xiao
AU  - Ma X
FAU - Han, Yue
AU  - Han Y
FAU - He, Guang-Sheng
AU  - He GS
FAU - Chen, Su-Ning
AU  - Chen SN
FAU - Xue, Sheng-Li
AU  - Xue SL
FAU - Zhao, Ye
AU  - Zhao Y
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 9927MT646M (Basiliximab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antilymphocyte Serum/therapeutic use
MH  - Basiliximab
MH  - Bone Marrow Transplantation
MH  - Child
MH  - Cyclosporine/therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/*prevention & control
MH  - Granulocyte Colony-Stimulating Factor/therapeutic use
MH  - Haploidy
MH  - Hematopoietic Stem Cell Mobilization
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Histocompatibility
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Male
MH  - Middle Aged
MH  - Peripheral Blood Stem Cell Transplantation
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
MH  - Recombinant Fusion Proteins/therapeutic use
MH  - Survival Rate
MH  - Transplantation Conditioning
MH  - Young Adult
EDAT- 2006/09/13 09:00
MHDA- 2009/05/29 09:00
CRDT- 2006/09/13 09:00
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2009/05/29 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
AID - 1000-467X2006081019 [pii]
PST - ppublish
SO  - Ai Zheng. 2006 Aug;25(8):1019-22.